Drug Profile
Research programme: cancer vaccines - Bavarian Nordic/National Cancer Institute
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator BN ImmunoTherapeutics; National Cancer Institute (USA)
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 05 Oct 2011 BN ImmunoTherapeutics establishes CRADA with National Cancer Institute for the development of vaccines for cancer
- 05 Oct 2011 Preclinical trials in Cancer in USA (Parenteral)